Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jan;156(2):510-524.
doi: 10.1053/j.gastro.2018.09.051. Epub 2018 Oct 1.

Targeted and Immune-Based Therapies for Hepatocellular Carcinoma

Tim F Greten  1 , Chunwei Walter Lai  2 , Guangfu Li  3 , Kevin F Staveley-O'Carroll  4
Affiliations
Review

Targeted and Immune-Based Therapies for Hepatocellular Carcinoma

Tim F Greten et al. Gastroenterology. 2019 Jan.

Erratum in

  • Corrigendum.
    [No authors listed] [No authors listed] Gastroenterology. 2024 Sep;167(4):819. doi: 10.1053/j.gastro.2024.06.024. Epub 2024 Jul 3. Gastroenterology. 2024. PMID: 38970609 No abstract available.

Abstract

Treatment options for patients with hepatocellular carcinoma are rapidly changing based on positive results from phase 3 trials of targeted and immune-based therapies. More agents designed to target specific pathways and immune checkpoints are in clinical development. Some agents have already been shown to improve outcomes of patients with hepatocellular carcinoma, as first- and second-line therapies, and are awaiting approval by the Food and Drug Administration or have been recently approved. We summarize the targeted and immune-based agents in trials of patients with advanced hepatocellular carcinoma and discuss the future of these strategies for liver cancer.

Keywords: Checkpoint Inhibitor; Human; Tumor.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: The authors declare they have no conflicts of interest.

Figures

Figure 1.
Figure 1.. Combination Therapy Options.
Different FDA-approved and experimental single agent anti-HCC thearpies are categorized by their mechanism. The aim is to combine two (or three) therapies that are either in the same class (e.g. anti-PD1 and anti-CTLA4) or across different classes of mechanism (e.g. immune checkpoint blockade and molecular targeting therapy) to achieve synergy.
See this image and copyright information in PMC

References

    1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359–86. - PubMed
    1. Clavien PA, Lesurtel M, Bossuyt PM, et al. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012;13:e11–22. - PMC - PubMed
    1. Vitale A, Peck-Radosavljevic M, Giannini EG, et al. Personalized treatment of patients with very early hepatocellular carcinoma. J Hepatol 2017;66:412–423. - PubMed
    1. European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018. - PubMed
    1. Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018;67:358–380. - PubMed

Publication types

MeSH terms